Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, ...

Practice of medicine could fundamentally change with these types of therapies,” said CEO Jaideep Dudani, of T cell engagers ...

Alzhemier’s disease could be diagnosed up to a decade earlier after the world’s biggest study of proteins is completed. The ...

Ouro is planning to leverage T cell engagers to deplete B cells and “reset” the immune system to treat immune-mediated ...

T cell engagers are having a moment, much like antibody-drug conjugates have for the past two years. The cell-depleting ...

This is the largest-ever primary fundraise in the Indian diagnostics segment and the first private equity round for Neuberg ...

Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...

Find insight on Zydus Lifesciences, Biotech and more in the latest Market Talks covering the Health Care sector.

Shingrix in 2017 received US FDA approval to prevent shingles in adults aged 50 and older. Since 2021, it has been approved for use in immunocompromised patients aged 18 and up. GSK estimates around ...

British drug maker GSK plc (GSK, GSK.L) announced Friday that the US Food and Drug Administration has accepted for review the ...

In the span of eight months, Big Pharma companies took over four of the hottest radiopharmaceutical players in the industry.

The 30th edition of the Dubai International Pharmaceuticals and Technologies Conference and Exhibition - DUPHAT 2025 concluded successfully, recording AED9.35 billion in direct and indirect trade ...